Agile Therapeutics Operating Income 2013-2023 | AGRX
Agile Therapeutics operating income from 2013 to 2023. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Agile Therapeutics Annual Operating Income
(Millions of US $) |
| 2023 |
$-20 |
| 2022 |
$-53 |
| 2021 |
$-71 |
| 2020 |
$-49 |
| 2019 |
$-19 |
| 2018 |
$-20 |
| 2017 |
$-27 |
| 2016 |
$-30 |
| 2015 |
$-33 |
| 2014 |
$-19 |
| 2013 |
$-13 |
| 2012 |
$-23 |
Agile Therapeutics Quarterly Operating Income
(Millions of US $) |
| 2023-12-31 |
$-4 |
| 2023-09-30 |
$-4 |
| 2023-06-30 |
$-5 |
| 2023-03-31 |
$-7 |
| 2022-12-31 |
$-7 |
| 2022-09-30 |
$-19 |
| 2022-06-30 |
$-11 |
| 2022-03-31 |
$-16 |
| 2021-12-31 |
$-22 |
| 2021-09-30 |
$-16 |
| 2021-06-30 |
$-17 |
| 2021-03-31 |
$-16 |
| 2020-12-31 |
$-17 |
| 2020-09-30 |
$-15 |
| 2020-06-30 |
$-10 |
| 2020-03-31 |
$-8 |
| 2019-12-31 |
$-6 |
| 2019-09-30 |
$-4 |
| 2019-06-30 |
$-4 |
| 2019-03-31 |
$-5 |
| 2018-12-31 |
$-4 |
| 2018-09-30 |
$-4 |
| 2018-06-30 |
$-5 |
| 2018-03-31 |
$-7 |
| 2017-12-31 |
$-6 |
| 2017-09-30 |
$-7 |
| 2017-06-30 |
$-7 |
| 2017-03-31 |
$-7 |
| 2016-12-31 |
$-8 |
| 2016-09-30 |
$-7 |
| 2016-06-30 |
$-8 |
| 2016-03-31 |
$-7 |
| 2015-12-31 |
$-9 |
| 2015-09-30 |
$-9 |
| 2015-06-30 |
$-8 |
| 2015-03-31 |
$-7 |
| 2014-12-31 |
$-7 |
| 2014-09-30 |
$-6 |
| 2014-06-30 |
$-3 |
| 2014-03-31 |
$-2 |
| 2013-12-31 |
|
| 2013-09-30 |
$-3 |
| 2013-06-30 |
$-3 |
| 2012-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.003B |
$0.020B |
|
Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.
|
